Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing.

Wang, Buhai; Fan, Yaqin; Zhang, Liying; Liu, Liqin; Ma, Yutong; Ma, Xiaosong; Huang, Yuxiang; Wu, Yinxia; Liang, Yichen; Xu, Yang; Wu, Xue

Wang, Buhai; Fan, Yaqin; Zhang, Liying; Liu, Liqin; Ma, Yutong; Ma, Xiaosong; Huang, Yuxiang; Wu, Yinxia; Liang, Yichen; Xu, Yang; Wu, Xue.

Afiliación

Wang B; Cancer Institute, Northern Jiangsu People's Hospital, Yangzhou, China.
Fan Y; Department of Medical Oncology, Jiaxing First Hospital, Jiaxing, China.
Zhang L; Cancer Institute, Northern Jiangsu People's Hospital, Yangzhou, China.
Liu L; Cancer Institute, Northern Jiangsu People's Hospital, Yangzhou, China.
Ma Y; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Ma X; Department of Oncology, Dalian Medical University, Dalian, China.
Huang Y; Cancer Institute, Northern Jiangsu People's Hospital, Yangzhou, China.
Wu Y; Cancer Institute, Northern Jiangsu People's Hospital, Yangzhou, China.
Liang Y; Cancer Institute, Northern Jiangsu People's Hospital, Yangzhou, China.
Xu Y; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Wu X; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.

Clin Med Insights Oncol ; 16: 11795549221075326, 2022.

Article en En | MEDLINE | ID: mdl-35197718

Palabras clave

Circulating tumor DNA; NGS; NSCLC; TMB; pembrolizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Med Insights Oncol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google